Houston-based Natural Language Processing (NLP) technology firm Melax Tech announced that it has joined in a sponsorship arrangement with Cambridge, Massachusetts-based BioSpark Group. BioSpark, a non-profit organization, is focused on establishing a scholar and entrepreneurship network and facilitating scientific translations within the biomedical field. Melax Tech is known internationally for its award-winning work in text annotation and extraction within the life sciences and biomedical domains.
By aligning with BioSpark Group, Melax Tech expects to continue growth in unstructured text data extraction and normalization in biopharma R&D applications, as members in BioSpark’s community could access Melax Tech’s CLAMP framework to explore uses for the technology.
Recommended AI News: Convious Raises $12M To Grow Its AI-Driven Ecommerce Platform For The Experience Economy
“The relationship between Melax Tech and BioSpark Group comes naturally, as both the group’s members and our company are invested in improving the quality of healthcare and care reporting, and breakthroughs in pharma and medicine,” said Andre Pontin, CEO of Melax Tech. “We look forward to showcasing our software capabilities in educational programs to BioSpark members during the coming year.”
The Melax Tech sponsorship will begin in January, 2022. Among the projects Melax Tech will offer BioSpark members is a webinar to introduce the range of possibilities Melax Tech’s CLAMP software offers to researchers.
Recommended AI News: Privitar Supports Broader Use And Sharing Of Data Across Borders With Introduction Of NOVLT Tokenization
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.